PeptideNerds

Survodutide

GLP-1 / Weight Loss Clinical Trials moderate evidence Track This Protocol
Alejandro Reyes

Written by Alejandro Reyes

Founder & Lead Researcher

PN

Reviewed by Peptide Nerds Editorial · Updated April 2026

Key Takeaway

Survodutide is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase 3 trials for obesity and metabolic liver disease.

Quick Facts
Type GLP-1 / Weight Loss
FDA Status Clinical Trials
Evidence Level Moderate
Typical Dose 0.6 mg to 4.8 mg weekly
Frequency Once weekly
Key Goals weight-loss, fat-loss

How it works

Activates both GLP-1 and glucagon receptors. The glucagon component increases energy expenditure and hepatic fat oxidation while GLP-1 reduces appetite.

Benefits

  • Up to 19% weight loss in Phase 2
  • Significant liver fat reduction
  • Potential MASH treatment

Side effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Similar to other GLP-1 agonists

Dosing protocol

Typical Dose

0.6 mg to 4.8 mg weekly

Frequency

Once weekly

Phase 3 dosing not yet finalized.

Deeper on Survodutide

Full breakdowns of every part of the Survodutide research base.

What you will need

Basic supplies for reconstitution and subcutaneous injection.

This page contains affiliate links. Learn more

Get the Survodutide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Key research

Survodutide for Obesity (Phase 2)

New England Journal of Medicine (2024) — PubMed

19.2% body weight loss at highest dose over 46 weeks.

Get the Survodutide cheat sheet

Dosing quick-reference, key studies, and side effect management — in your inbox.

Compare Survodutide

Related peptides

Get the Peptide Starter Kit (free)

Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.

Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.